Taflotan Adverse Reactions

Concise Prescribing Info Bahasa Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Caution For Usage Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Adverse Reactions

Adverse drug reactions (including abnormal change in laboratory test values) were reported in 326 of 483 patients (67.5%). The major adverse reactions were conjunctival hyperaemia in 151 patients (31.3%), abnormality in eyelashes in 93 patients (19.3%), itching in 85 patients (17.6%), eye irritation in 65 patients (13.5%), and iris pigmentation in 39 patients (8.1%), etc.
Clinically significant adverse reaction: Iris pigmentation (8.1%): Since iris pigmentation may occur, patients should be examined periodically, and administration should be discontinued depending on the clinical status when iris pigmentation is observed.
Other adverse reactions: If an adverse drug reaction is observed, appropriate measures such as discontinuing administration should be taken. (See Table 3.)

Click on icon to see table/diagram/image

View ADR Reporting Link

Taflotan Adverse Reactions

tafluprost

Manufacturer:

Santen

Marketer:

Meiji